88ACTIVITIES
1ORGS REPRESENTED
27BILLS
Organizations represented
1Orgs whose LD-2 filings list Emily as an active lobbyist, sorted by activity volume.
Bills they file on
27H.R. 126245 mentions
S. 93245 mentions
H.R. 616630 mentions
H.R. 167230 mentions
S. 52730 mentions
S. 52630 mentions
S. 86430 mentions
H.R. 642330 mentions
S. 109529 mentions
S. 109629 mentions
S. 109729 mentions
H.R. 326928 mentions
S. 227628 mentions
H.R. 648528 mentions
S. 4328 mentions
+ 12 more bills referenced in their activities
Topics in Filings
218Policy topics Emily files on across all their LD-2 activities.
Medical Countermeasure Priority Review Voucher Reauthorization×141
CMMI: GLOBE and GUARD Models×98
Lowering Drug Costs for American Families Act×74
Antimicrobial Resistance×73
National Coverage Determination×73
R&D Funding for Medical Countermeasures×73
International Pricing Policies×70
Pharmacy Benefit Manager Transparency Act×60
CMMI Authority×60
Pandemic Preparedness×60
Preserve Access to Affordable Generics and Biosimilars Act×59
Prescription Pricing for the People Act×59
Show all 218 topics (+206 more) ▾
FY 2026 Appropriations for Agencies×58
Centers for Disease Control and Prevention×58
Health Resources and Services Administration×58
HHS Office of Infectious Disease and HIV/AIDS Policy×58
Biodefense/Biomedical/Emergency Preparedness Research×58
Development and Procurement×58
Funding for Strategic National Stockpile×58
Stop STALLING Act×58
FY 2026 Appropriations for Specific Issues×58
Most Favored Nation Drug Pricing Proposals×57
Administration for Strategic Preparedness and Response×56
Biomedical Advanced Research and Development Authority×56
Pediatric Priority Review Voucher×56
340B Rebate Rule×56
Maintaining Investments and New Innovation×46
Clinical Trial Data in China×46
Drug Pricing×44
Vaccines and Infectious Diseases×44
Development and Procurement Issues×44
Interagency Patent Coordination and Improvement Act×44
Drug Supply Chain Management×44
Supply Chain Issues×44
Food & Drug Administration×42
Big Savings Act×42
MCM PRV Reauthorization×31
Alternative Funding Programs×30
Biosimilar Red Tape Elimination Act×30
Quality & Distribution×30
Advanced Manufacturing×30
Drug Shortages×30
Supply Chain Integrity and Traceability×30
Medicare Drug Price Negotiation Act×30
Patient Cost-Sharing and Implementation×30
Alternative Payment Arrangements for Gene Therapies×30
Drug Benefit Design×30
Pricing and Rebates×30
National Defense Authorization Act×30
Orphan Drug Tax Credit×30
SAFE STEP Act×30
Adult Immunization×30
Let Injured Americans Be Legally Empowered×30
Vaccine Access Improvement Act×30
Vaccine Injury Compensation Modernization×30
Vaccine Injury Compensation Program×30
Vaccine Safety Net and Vaccine Infrastructure×30
Value of Vaccines and Vaccine Confidence×30
Pandemic Preparedness -R&D Funding for Medical Countermeasures×29
Increasing Transparency in Generic Drug Application×29
Modernizing and Ensuring PBM Accountability×29
Medicaid VBPs for Patients×29
Support of Patient Premiums and Cost-Sharing Obligations×29
MCM Manufacturing & Capacity×29
Average Manufacturer Price Calculations×29
Centers for Medicare and Medicaid×28
National Institutes of Health×28
Funding for Section 317×28
Funding for Women's Health Research×28
National Defense Authorization Act 2027×28
Risky Research Review Act×28
Biosimilars Competition×28
Data Privacy Working Group Draft×28
CMMI×28
Non-Opioid Analgesics Orphan Drug Issues×28
Pediatric Priority Review Voucher Pandemic Preparedness×28
Value-based Contracting and Communications×28
Mandating Exclusive Review of Individual Treatments×17
Value-Based Purchasing×17
Executive Order on Access to Affordable Life-Saving Medications×16
Program Implementation & Oversight×16
PROTECT 340B Act×16
SUSTAIN 340B Act×16
Reimbursement Cell & Gene Therapy×16
Restrictions on Intellectual Property Rights Drug Pricing×16
Access to Innovative Treatments Act×16
Strengthening Innovation in Medicare and Medicaid Act×16
Medicare Part B Physician-Administered Products×16
Maternal Immunization×16
CICP×15
Influenza Planning & Response×15
Prescription Drug User Fee Act×15
Project Bioshield×15
Section 317 Immunization Program×15
Vaccine Injury Compensation Program 340B Drug Discount Program×15
Accelerated Approval Artificial Intelligence×15
MCM PRV Program Reauthorization×15
State Strategic Stockpile Act×15
VICP Loopholes×15
WHO Pandemic Preparedness Accord Biosimilars×15
Interchangeability and Pharmacy Substitution×15
FDA Hiring Flexibility×15
Promising Pathway Act×15
Compounding Pharmacies×15
Contract Manufacturing Ecosystem in the United States×15
Affordable Prescriptions for Patients Act×15
Medication Affordability and Patient Integrity Act×15
COVID-19 Pricing-Related Provisions×15
DRUG Act×15
Generic Drug Entry×15
Generic Drug Application Review Reforms×15
Incentives for Generic Entry Issues×15
FDA Modernization×15
Act 3.0 Medicaid×15
Coverage of Accelerated Approval Products×15
Innovation in Pediatric Drugs Act×15
Retaining Access and Restoring Exclusivity×15
Access to Innovative Treatments×15
Patient Cost-Sharing and Smoothing×15
Step Therapy×15
MCM R&D Incentives×15
PASTEUR ACT×15
Vaccine and Antimicrobial Resistance Product Development and Incentives×15
Vaccine Quality Measure×15
Vaccine Safety×15
Advanced Research Projects Agency for Health×15
Funding for Medical Countermeasures×15
Pandemic Flu×15
VICP/CICP Antimicrobial Resistance Biodefense Research×15
Vaccines and Infectious Diseases 340B Drug Discount Program×15
Accelerated Approval Antimicrobial Resistance Artificial Intelligence×15
Biosimilar Copay×15
Biosimilars Red Tape Elimination Act×15
Compounded Medicines×15
PBM Reform×15
Medicaid Drug Rebate Program×15
Most Favored Nation in Medicaid×15
NSCEB Recommendations Opioid Crisis×15
Countermeasures Injury Compensation Program×15
Vaccine Safety and Quality×15
VICP/CICP Capital Formation Incentives×15
Cameron's Law Pandemic Preparedness Research & Development Tax Credit Reforms×15
One Big Beautiful Bill Act×15
Expensing of R&D Expenditures×15
Countermeasure Injury Compensation Fund Amendment Act×15
CMMI Models: GLOBE and GUARD×14
Vaccine Access & Compensation×14
Disease X Act×14
Gain of function×14
SAFE Risky Research Act×14
White House National Biodefense Strategy×14
Purple Book Draft×14
American Privacy Rights Act×14
Consumer Data Privacy and Security Act×14
Diagnostics and Personalized Medicine Regulation and Oversight×14
Diversity & Inclusion×14
Decentralized Clinical Trials Drug Evaluation and Review×14
PDUFA VII Implementation×14
PDUFA VIII Negotiations Drug Importation Drug Manufacturing×14
Biosecurity Modernization×14
NSC/OSTP priorities×14
Nucleic acid synthesis security and biotechnology governance×14
Coverage and Reimbursement×14
Rare Disease Pilot Program Reimbursement and Coverage of Innovative Products×14
VICP/CICP Biodefense Research×14
WHO Pandemic Preparedness Accord Pandemic Preparedness×14
CDC Reform×14
FDA Hiring Staffing Drug Importation Drug Manufacturing×14
Tariffs Foreign Drug Data Protection Laws Medicaid×14
Encouraging Innovation Benefit Design to Lower Costs for Seniors Act×14
Precision Medicine Initiative Reimbursement and Coverage of Innovative Products×14
American Innovation and Jobs Act×14
Incentives for Domestics Manufacturing Orphan Drug Issues×14
R&D Payroll Credit Vaccines and Infectious Disease×14
BIOSECURE Act×4
Monoclonal Antibody Coverage and Utilization×3
ASPR×2
National Institutes of Health FY 2026 Appropriations for Specific Issues×2
SUPPORT Act×2
Orphan Drug Issues×2
Creating Hope Reauthorization×1
PPRV×1
340B ACCESS Act×1
340B Accountability Act×1
House GOP RFI on Supply Chain×1
National Defense Authorization Act 2026×1
Reasonable Pricing Clauses in BARDA Contracts×1
Synthetic Nucleic Acid Synthesis Screening×1
PDUFA VIII Negotiations×1
Drug Manufacturing×1
Safe, and Secure American Bioeconomy×1
Bill to address patent thickets×1
Biologics Competition Act×1
Medicare Negotiation and Competitive Licensing Act×1
Enhanced Access to Affordable Medicines Act×1
Medicaid Drug Rebate Program Rule×1
Most Favored Nation Pricing Opioid Crisis×1
Finding Orphan-Disease Remedies with Antifungal Research and Development×1
Temporarily Refundable R&D Credit×1
Reimbursement and Coverage of Innovative Products×1
Administrative Rebate Rule×1
Lower Costs×1
More Transparency Act×1
Prescription Drug Price Relief Act×1
Protected Classes×1
BARDA×1
HHS Reorganization×1
MCM PRV Program CDC Reform×1
340B Rebate Pilot Program×1
Bio COMPETES×1
FDA Hiring Flexibility Drug Manufacturing×1
Most Favored Nation Pricing×1
Foreign Drug Data Protection Laws Medicaid×1
Vaccine Access×1
Vaccines for Children Program×1
Non-Opioid Analgesics×1
Pediatric Priority Review Voucher Program Reauthorization×1
Administration Rebate Rule×1
Issue mix
LDA general-issue codes weighted by activity count.
Health Issues15
Medical/Disease Research/Clinical Labs15
Medicare/Medicaid15
Taxation/Internal Revenue Code15
Budget/Appropriations14
Homeland Security14